Vera Therapeutics CEO exercises options, sells shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4/A
Rhea-AI Filing Summary
Vera Therapeutics, Inc. president and CEO Marshall Fordyce exercised stock options covering 46,250 shares of Class A Common Stock on July 7, 2026 at an exercise price of $2.8968 per share, and on the same date sold 46,250 shares in multiple transactions at weighted-average prices between $40.7762 and $43.5947. The option, which vests over four years and expires on December 15, 2030, showed 525,801 derivative securities beneficially owned following the reported exercise. The sales were made pursuant to a Rule 10b5-1(c) trading plan adopted on January 9, 2026.
Insider Trade Summary 10b5-1
Exercise and Sale: 46,250 shares ($1.82M approx. pre-tax spread)
Exercise and Sale
6 txns
Insider
Fordyce Marshall
Role
PRESIDENT AND CEO
Sold
46,250 shs ($1.96M)
Approx. gross sale proceeds
$1.96M
Approx. exercise cost
$134K
Approx. pre-tax spread
$1.82M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F1, F7 | 46,250 | $0.00 | $0.00 |
| Exercise | Class A Common Stock F1 | 46,250 | $2.8968 | $134K |
| Sale | Class A Common Stock F2, F3, F1 | 1,000 | $40.7762 | $41K |
| Sale | Class A Common Stock F2, F4, F1 | 32,550 | $42.0736 | $1.37M |
| Sale | Class A Common Stock F2, F5, F1 | 10,500 | $42.8578 | $450K |
| Sale | Class A Common Stock F2, F6, F1 | 2,200 | $43.5947 | $96K |
Holdings After Transaction:
Stock Option (Right to Buy) — 525,801 contracts (Direct);
Class A Common Stock — 235,244 shares (Direct)
Footnotes (7)
- F1. This amended Form 4 is filed to reflect the option exercise that occurred on July 7, 2026 and correct the amounts reported in Column 5 "Amount of Securities Beneficially Owned Following Reported Transaction(s)".
- F2. The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
- F3. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.39 to $41.31, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- F4. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.40 to $42.39, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- F5. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.40 to $43.38, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- F6. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $43.42 to $43.97, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- F7. 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vested monthly thereafter.
Key Figures
Options exercised: 46,250 shares
Exercise price: $2.8968 per share
Shares sold: 46,250 shares
+5 more
8 metrics
Options exercised
46,250 shares
Stock options exercised for Class A Common Stock on July 7, 2026
Exercise price
$2.8968 per share
Exercise price of stock options converted into Class A Common Stock
Shares sold
46,250 shares
Total Class A Common shares sold across four sale transactions on July 7, 2026
Sale price range (weighted-average groups)
$40.7762–$43.5947 per share
Weighted-average prices for grouped sale transactions on July 7, 2026
Derivative securities post-exercise
525,801
Amount of derivative securities beneficially owned following the option exercise
Option expiration date
December 15, 2030
Expiration date of the exercised stock option
10b5-1 plan adoption date
January 9, 2026
Date the Rule 10b5-1(c) trading plan governing the sales was adopted
Initial vesting date
December 16, 2021
Date when 1/4 of the option shares vested; remaining 1/48 monthly thereafter
Key Terms
Rule 10b5-1(c), weighted-average price, Stock Option (Right to Buy), Class A Common Stock, +1 more
5 terms
Rule 10b5-1(c) regulatory
"plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c)"
Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.
weighted-average price financial
"The price reported is a weighted-average price. These shares were sold"
Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
Class A Common Stock financial
"underlying_security_title": "Class A Common Stock""
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What transactions did VERA CEO Marshall Fordyce report on this Form 4/A?
Marshall Fordyce reported exercising options for 46,250 shares of Vera Therapeutics Class A Common Stock at $2.8968 per share and selling 46,250 shares in multiple transactions on July 7, 2026.
What were the terms of the Vera Therapeutics (VERA) stock options exercised by the CEO?
The exercised stock options covered 46,250 shares at an exercise price of $2.8968 per share. One quarter vested on December 16, 2021, with 1/48 vesting monthly thereafter, and the options expire on December 15, 2030.
How many derivative securities does the VERA CEO report owning after the option exercise?
Following the reported option exercise, Marshall Fordyce is shown as beneficially owning 525,801 derivative securities related to Vera Therapeutics, based on the post-transaction amount for the exercised stock option position.
Is this VERA Form 4/A an amendment and what does it correct?
Yes. The report explains it is filed to reflect the option exercise on July 7, 2026 and to correct the amounts shown in Column 5, “Amount of Securities Beneficially Owned Following Reported Transaction(s).”
AI-generated analysis. How Rhea-AI works. Not financial advice.
